About this Guide
This guide provides supporting information for the Nucala Dosing Calculator. It outlines the standard dosing regimens for Nucala (mepolizumab) based on its FDA-approved indications, explains how the calculator determines its outputs, and answers frequently asked questions about its administration.
Outputs
After inputting the required patient information, the calculator provides the following key outputs for subcutaneous administration:
- Recommended Dose: The precise amount of Nucala in milligrams (mg), which can be 40 mg, 100 mg, or 300 mg.
- Administration Frequency: The standard dosing schedule, which is once every 4 weeks for all approved indications.
- Route of Administration: The calculator is exclusively for subcutaneous (SC) injection.
How to Use
To determine the appropriate Nucala dose, follow these steps in the calculator:
- Select Patient Indication: Choose the relevant condition from the dropdown menu (e.g., Severe Eosinophilic Asthma, CRSwNP).
- Enter Patient Age (if required): For Severe Eosinophilic Asthma (SEA), an age field will appear. Enter the patient's age in years, as dosing differs for pediatric patients. This step is not required for other indications.
- Calculate Dose: Click the "Calculate Dose" button to view the recommended dosing information.
Dosing Overview
The following are the standard subcutaneous doses for Nucala administered once every 4 weeks, as reflected in the calculator's logic.
- Severe Eosinophilic Asthma (SEA):
- Adults and adolescents aged 12 years and older: 100 mg
- Pediatric patients aged 6 to 11 years: 40 mg
- Chronic Rhinosinusitis with Nasal Polyps (CRSwNP):
- Adults aged 18 years and older: 100 mg
- Eosinophilic Granulomatosis with Polyangiitis (EGPA):
- Adults aged 18 years and older: 300 mg (administered as three separate 100 mg injections)
- Hypereosinophilic Syndrome (HES):
- Adults and pediatric patients aged 12 years and older: 300 mg (administered as three separate 100 mg injections)
Switching
There are no specific tapering schedules required when switching patients from other therapies (e.g., oral corticosteroids) to Nucala. Reductions in corticosteroid doses should be gradual and performed under the direct supervision of a healthcare provider. Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of Nucala therapy.
Missed Dose
If a planned dose of Nucala is missed, the patient should be instructed to administer it as soon as possible. The subsequent dosing schedule should then be adjusted to maintain the 4-week interval. If unsure, the patient should consult their healthcare provider for guidance on their next injection.
Safety Alerts
Important: This information is not a substitute for the full Prescribing Information. Healthcare professionals must review the complete label for all contraindications, warnings, precautions, and adverse reactions before prescribing or administering Nucala.
Key safety considerations include:
- Hypersensitivity Reactions: Serious reactions, including anaphylaxis, can occur after Nucala administration. These may occur hours or days after the injection.
- Acute Asthma Symptoms: Nucala should not be used to treat acute bronchospasm or status asthmaticus.
- Infections: Herpes zoster has occurred in patients receiving Nucala. Consider vaccination if medically appropriate.
FAQ
Why is age required only for Severe Eosinophilic Asthma (SEA)?
For SEA, the Nucala dose is age-dependent. Patients aged 6 to 11 receive a 40 mg dose, while those 12 and older receive 100 mg. For other indications like CRSwNP, EGPA, and HES, the approved dosing is not stratified by different age groups in the same way.
How is the 300 mg dose for EGPA or HES administered?
The 300 mg dose is given as three separate 100 mg subcutaneous injections during a single administration session. The prescribing information recommends injecting at least 5 cm (approximately 2 inches) apart if administered in the same body area (e.g., abdomen, thigh).
Does this tool calculate weight-based dosing?
No. The subcutaneous dosing for Nucala is fixed based on indication and, in the case of SEA, age. It is not adjusted based on patient weight.
Can I use this calculator for intravenous (IV) Nucala?
No, this calculator is designed exclusively for subcutaneous Nucala administration. The intravenous formulation has a different indication (for SEA patients aged 6 years and older) and dosing regimen, which is not covered by this tool.
What is the Nucala dose for a 10-year-old child with SEA?
Based on the calculator's logic and FDA guidelines, a 10-year-old child with SEA would receive a 40 mg subcutaneous injection every 4 weeks.
How often is Nucala administered?
For all approved indications calculated by this tool, Nucala is administered subcutaneously once every 4 weeks.
What if a patient's indication is not listed in the calculator?
The calculator only includes indications for which Nucala has a specific FDA-approved subcutaneous dosing regimen. For any off-label use or unlisted conditions, consult the primary literature and exercise independent clinical judgment.
Is a loading dose required for Nucala?
No, a loading dose is not required for Nucala. Therapy is initiated with the standard maintenance dose administered every 4 weeks.
References
- Nucala (mepolizumab) Prescribing Information. U.S. Food and Drug Administration.
- Nucala Dosing & Administration. GSK Pro for Healthcare Professionals.
- Mepolizumab Injection. MedlinePlus, National Library of Medicine.
- Nucala - mepolizumab injection, powder, lyophilized, for solution. DailyMed, U.S. National Library of Medicine.
